UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE13a-16 OR15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of November 2019
Commission File Number:001-39131
LIMINAL BIOSCIENCES INC.
(Translation of registrant’s name into English)
440 Armand-Frappier Boulevard, Suite 300
Laval, Québec
H7V 4B4
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form20-F or Form40-F:
☒ Form20-F ☐ Form40-F
Indicate by check mark if the registrant is submitting the Form6-K in paper as permitted by RegulationS-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form6-K in paper as permitted by RegulationS-T Rule 101(b)(7): ☐
INCORPORATION BY REFERENCE
This Report on Form6-K shall be deemed to be incorporated by reference into the registration statement on FormF-10 (RegistrationNo. 333-234652) of Liminal BioSciences Inc. (including any prospectuses forming a part of such registration statement) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.
EXHIBIT LIST
Exhibit | Description | |
| 99.1 | Share Purchase Agreement, dated November 3, 2019, by and between Liminal BioSciences Inc. and Gamma Biosciences GP LLC. | |
| 99.2 | Material Change Report, dated November 13, 2019. | |
| 99.3 | New release, dated November 4, 2019. | |
| 99.4 | New release, dated November 11, 2019. | |
| 99.5 | First Amendment to the Consolidated Loan Agreement between Structured Alpha LP, Liminal Biosciences Inc., Prometic BioTherapeutics Inc., Liminal R&D Biosciences Inc., Prometic Bioproduction Inc., NantPro Biosciences, LLC, Prometic Plasma Resources Inc., Liminal Biosciences Holdings Limited, Liminal Biosciences Limited, Prometic Biotherapeutics Ltd, Telesta Therapeutics Inc. and Prometic Plasma Resources (USA) Inc., dated as of November 11, 2019. | |
| 99.6 | Material Change Report, dated November 15, 2019. | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Liminal BioSciences Inc. | ||||||
| Date: November 15, 2019 | By: | /s/ Kenneth Galbraith | ||||
| Name Kenneth Galbraith | ||||||
| Title: Chief Executive Officer | ||||||
